Çàðåãèñòðèðîâàòüñÿ

Ïîõîæèå òåìû

  1. Ëå÷åíèå ïàðòíåðà ïðè ïàïèëëîìàâèðóñíîé èíôåêöèè
    îò ÌÌÓ ¹37 â ðàçäåëå Âåíåðîëîã-äåðìàòîëîã
    Îòâåòîâ: 78
    : 14.01.2022, 12:33
  2. Ëå÷åíèå ïàðòíåðà?!
    îò ibelkov@bk.ru â ðàçäåëå Ãèíåêîëîã-àêóøåð, áåðåìåííîñòü, ðîäû
    Îòâåòîâ: 0
    : 01.09.2004, 19:30
  3. Äîêòîð, çäðàâñòâóéòå, â òå÷åíèå 1, 5 ëåò èåþ ïîñòîÿííîãî ïàðòíåðà, íî îðãàç...
    îò Àëÿ-ëÿ â ðàçäåëå Ñåêñ è ñåêñîïàòîëîãèÿ, îòíîøåíèÿ.
    Îòâåòîâ: 2
    : 04.08.2004, 15:02
  4. Îòâåòîâ: 1
    : 19.06.2004, 08:16
  5. Óâàæàåìûé êîëëåãà! Ïî÷åìó ïðè ïàïèëëîìàâèðóñíîé èíôåêöèè íàçíà÷àþò Âèâåðîí ...
    îò Àðòåì â ðàçäåëå Ãèíåêîëîã-àêóøåð, áåðåìåííîñòü, ðîäû
    Îòâåòîâ: 1
    : 09.06.2004, 06:04
  1. Saty73
    #16
    ×èòàòåëü Íåäóã.Ðó
    Çäðàâñòâóéòå!



    Æàëü , ÷òî íàøà äèñêóññèÿ îòîøëà îò òåìû. Äåëî íå â òîì, ÷òî HPV 16 è 18 íå âûçûâàþò îñòðîêîíå÷íûõ êîíäèëîì (ÎÊ) , à â ïîäõîäå, ÷òî ëå÷èòü ïàðòíåðà íóæíî òîëüêî ïðè íàëè÷èè ó íåãî ÎÊ. Ê ïðèìåðó HPV 16 è 18 ìîãóò âûçûâàòü ïëîñêèå êîíäèëîìû , PIN è ðàê ó ìóæ÷èí. Äà, â åâðîïåéñêèõ ñòðàíàõ ýòî ìàëîçíà÷èìî, íî â Àçèè, íàïðèìåð, ýòî ïðîáëåìà. Êðîìå òîãî, ñàìè ðàáîòû ïî íåýôôåêòèâíîñòè ëå÷åíèÿ ïàðòíåðà äàòèðîâàíû 1991 ã. Òðóäíî îáüÿñíèòü ïàöèåíòó , äà è äîêòîðó, ÷òî çàðàçèòüñÿ îò ïàðòíåðà HPV ìîæíî, à ëå÷èòü ïàðòíåðà ïðè ýòîì íå íóæíî. Ó÷èòûâàÿ íèçêóþ ýôôåêòèâíîñòü ïðåçåðâàòèâîâ äëÿ ïðåäîòâðàùåíèÿ ïåðåäà÷è HPV, ôàêòè÷åñêè íàäî ðåêîìåíäîâàòü ïîëíîå âîçäåðæàíèå äî âîçìîæíîé ýëèìèíàöèè âîçáóäèòåëÿ ó ìóæ÷èíû.

    Òåì áîëåå , ñêðèíèíã íà ÂÏ× ó ìóæ÷èí ïîêà íå ðåêîìåíäîâàí, à íå äîêàçàíà åãî áåñïîëåçíîñòü!

    Òåñòû íà ÂÏ× ó æåíùèí áûëè îäîáðåíû FDA è îíêîëîãàìè òîëüêî â ïðîøëîì ãîäó, à ïðèìåíÿëèñü óæå äàâíî.

    Òîëüêî ïðèìåíÿÿ òåñò íà ïðàêòèêå. ìîæíî óáåäèòüñÿ â åãî ïîëåçíîñòè.



    Êñòàòè, ëþáîïûòíàÿ öèòàòà èç ñòàòüè À.Ñ. Âèøíåâñêîãî è Í.Ð.Ñàôðîííèêîâîé (Ïðàêòè÷åñêàÿ îíêîëîãèÿ, ò.3 ¹3-2002ã):

    "Èíòåðåñíî îòìåòèòü, ÷òî ïî ïðîáëåìå ëåêàðñòâåííîãî è êîìáèíèðîâàííîãî ëå÷åíèÿ ÂÏ× ìû íå âñòðåòèëè íè îäíîé ðàáîòû ( îçíàêîìèâøèñü ïî ñåòè Èíòåðíåò ñ 550 ðåôåðàòàìè ñòàòåé, ïîñâÿùåííûõ ýòîé òåìå) , â êîòîðûõ áû óïîìèíàëèñü ïðåïàðàòû - àíàëîãè íóêëåîòèäíûõ îñíîâàíèé, òàêèõ êàê àöèêëîâèð è äðóãèå, êîòîðûå øèðîêî ïðèìåíÿþòñÿ ïðè ãåðïåòè÷åñêîé èíôåêöèè. Ïî âèäèìîìó, ýòè ñîåäèíåíèÿ ïðè ÂÏ× - èíôåêöèè íå ýôôåêòèâíû ."(?!!)

    Ïðè òàêîé ëîãèêå íîâûõ ìåòîäîâ ëå÷åíèÿ íå áóäåò âîîáùå. Íåò ðàáîò íà Çàïàäå - çíà÷èò ýòî òóïèê.

    Ìîæåò ñêàçûâàåòñÿ íàøà òðàäèöèÿ âñå íîâîå èñêàòü òîëüêî íà Çàïàäå?

    Êñòàòè , ðàáîò ïî ïðèìåíåíèÿ Âàëòðåêñà ïðè ÂÏ× ÿ òîæå íå íàøåë, îäíàêî íà ôîðóìàõ íåêîòîðûå ãèíåêîëîãè åãî ðåêîìåíäóþò.

    Äîêàçàòåëüñòâ íåýôôåêòèâíîñòè åãî ÿ íå íàøåë òîæå.

    Ìîæåò. ó êîãî -òî åñòü îïûò ëå÷åíèÿ Âàëòðåêñîì äèñïëàçèé èëè ÂÏ×?

  2. alenyshka
    #17
    ×èòàòåëü Íåäóã.Ðó
    Ïðîñòèòå, Àëåêñ!

    Îáåùàþ íå âñòðåâàòü äî òåõ ïîð, ïîêà íå íàéäó ÷òî-íèáóäü òîëêîâîå ïî èíòåðåñóþùåé Âàñ òåìå.



    Ñ óâàæåíèåì

  3. MamaNaci
    #18
    ×èòàòåëü Íåäóã.Ðó
    ßíà!

    Âñ¸ çíàíèå (èëè íåçíàíèå) âðà÷à îá ýòèîëîãèè, ïàòîôèçèîëîãèè çàáîëåâàíèé, âðîæäåííûõ èëè ïðèîáðåòåííûõ ïàòîëîãè÷åñêèõ îòêëîíåíèÿõ îðãàíèçìà, ïàòîãåííîé ìèêðîôëîðå è ò.ï. – îò ïàòîôèçèîëîãîâ, áèîõèìèêîâ, ãåíåòèêîâ, ìèêðîáèîëîãîâ, âèðóñîëîãîâ è äð. Åñëè âðà÷ ïîëàãàåò, ÷òî äëÿ ëå÷åíèÿ åìó âïîëíå äîñòàòî÷íî ïðîñòî ÷åòêî ïî ïóíêòàì âûïîëíÿòü íàïèñàííûå ñòàíäàðòû è ðåêîìåíäàöèè, îòñëåæèâàòü ñðàâíèòåëüíûå ñòàòèñòè÷åñêèå èñïûòàíèÿ ëåêàðñòâ, òî, ìîãó ñîãëàñèòüñÿ, îáùàòüñÿ ñî ñìåæíûìè ñïåöèàëèñòàìè äëÿ òàêèõ âðà÷åé - ëèøíåå. Íî êîãäà âðà÷ êàñàåòñÿ ïðè÷èíî-ñëåäñòâåííûõ âîïðîñîâ çàáîëåâàíèé, âûøå ïåðå÷èñëåííûå ñïåöèàëèñòû ìîãóò ðàçáèðàòüñÿ â íèõ çíà÷èòåëüíî ëó÷øå.

    P.S. Ýòî, â îáùåì-òî, íå î ã-íå Çàéöåâå, à î åãî, êàê Âû âûðàçèëèñü, êîëëåãàõ, êîòîðûå äîëæíû íå âûñîâûâàòüñÿ ñî ñâîåãî ôîðóìà.

  4. Àçàò
    #19
    ×èòàòåëü Íåäóã.Ðó
    Ì äà, âåäü íåñêîëüêî ðàç çàðåêàëñÿ âñòóïàòü ñ ã-íîì Æèâîâ â äèñêóññèè. Àëåêñåé Âèêòîðîâè÷, ìîæåòå î÷åðåäíîé ðàç íàõàìèòü, íî äèñêóòèðîâàòü ñ Âàìè äåéñòâèòåëüíî íåïðèÿòíî. Èç ìíîæåñòâà ñîîáùåíèé èç ðàçëè÷íûõ ñòðàí è êëèíèê, âêëþ÷àÿ ëþáèìûå äâîéíûå ðàíäîìèçèðîâàííûå, êîòîðûå Âû â óïîð íå æåëàëè çàìå÷àòü, îêàçûâàåòñÿ, ñëåäóåò, ÷òî âûëå÷åííûå áîëüíûå - ýòî ìî¸ âîñïàëåííîå âîîáðàæåíèå! È ãëàâíîå, ñóäèòå - òî ñ òàêîé íàõðàïèñòîé ñàìîóâåðåííîñòüþ Âû î ìåòîäèêå, î êîòîðîé è ïðåäñòàâëåíèÿ íå èìååòå (êàê, âïðî÷åì, è î öåëîì ðÿäå äðóãèõ âåùåé).

  5. Djamka
    #20
    ×èòàòåëü Íåäóã.Ðó
    Íó ÷òî æ, î ïðàêòè÷åñêîé ïîëüçå ò.í. èììóíîãðàììû ó áîëüíûõ HPV èíäóöèðîâàííûõ çàáîëåâàíèé Âû òàê íè÷åãî è íå îòâåòèëè è íå ñîîáùèëè. Î òîì ïî÷åìó ÎÒ â òå÷åíèå ìíîãèõ ëåò "óñïåøíîãî" ïðèìåíåíèÿ ïî-ïðåæíåìó âíå âñåõ è âñÿ÷åñêèõ ñòàíäàðòîâ ìåä. ïîìîùè - ñêàçàòü íå÷åãî. Îïÿòü çàáàëòûâàíèÿ, äåòñêèå îáèäû, îáâèíåíèÿ îïïîíåòîâ â òîì, ÷òî îíè ÷åãî òî íå çíàþò è ò.ï. ß âàì ñêàæó åùå îäíó âåùü. Ñ ÷åëîâåêîì, êîòîðûé ïîñëå äâàäöàòè ïðîñüá äåëàåò âèä, ÷òî íå ïîíèìàåò î ÷åì åãî ñïðàøèâàþò ïóñêàòüñÿ â íåêèå íàó÷íûå äèñêóñèè íèæå âñÿêîãî äîñòîèíñòâà. Âû ÷òî õîòèòå, ÷òîáû ÿ ñ âàìè îáñóæäàë íþàíñû ïðîòèâîâèðóñíîãî èììóíèòåòà ïðè HPV-èíôåêöèÿõ? Êàê ìîæíî îáñóæäàòü ñ âàìè íþàíñû, åñëè íà âïîëíå îáùèå âîïðîñû ó Âàñ îòâåòà íåò. Òàê âîò Âëàäèìèð ßêîâëåâè÷! Âû ëèáî áåðåòå ñâîè ñëîâà îáðàòíî êàñàåìî ëþáîé ïðàêòè÷åñêîé öåííîñòè ò.í. èììóíîãðàììû ïðè HPV-èíôåêöèÿõ, ëèáî ÿ ïðîäîëæó ñ÷èòàòü Âàñ ÷åëîâåêîì äëÿ êîòîðîãî èäåîëîãèÿ äîðîæå ïðàâäû è ôàêòà. À ê ÷åìó ïðèâåëà äåÿòåëüíîñòü ïîäîáíûõ ëþäåé - èñòîðèÿ çíàåò íåìàëî ïðèìåðîâ.

  6. Âèíñåí
    #21
    ×èòàòåëü Íåäóã.Ðó
    Óâ. äîêòîð Æèâîâ!



    Âîçâðàùàÿñü ê âîïðîñó î òèïàõ ÂÏ× è ðóêîâîäñòâàõ, íå ìîãó íå ïðèâåñòè öèòàòó èç òîãî æå ðóêîâîäñòâà ÑDÑ 2002:



    HPV types 16, 18, 31, 33, and 35 are found occasionally in

    visible genital warts and have been associated with external

    genital (i.e., vulvar, penile, and anal) squamous intraepithelial

    neoplasia (i.e., squamous cell carcinoma in situ, bowenoid

    papulosis, Erythroplasia of Queyrat, or Bowen’s disease of the

    genitalia). These HPV types also have been associated with

    vaginal, anal, and cervical intraepithelial dysplasia and squamous

    cell carcinoma. Patients who have visible genital warts

    can be infected simultaneously with multiple HPV types.



    Ò.å. íå òàê óæ íåïðàâ áûë Â.ß., ãîâîðÿ î âîçìîæíîé ðîëè ÂÏ× 16,18 ïðè ðàçâèòèè îñòðîêîíå÷íûõ êîíäèëîì.( Ðåäêî, íî áûâàåò âñå-òàêè!)



    Îá ýòîì æå ÿ ïèñàë è î ðóêîâîäñòâàõ – îíè ìîãóò áûëü ïðàâèëüíûìè , íî íåïîëíûìè.



    Ñîáåñåäíèêè! áóäüòå âçàèìíî âåæëèâû! È ïðè ÷åì çäåñü îçîíîòåðàïèÿ?

  7. ASH2
    #22
    ×èòàòåëü Íåäóã.Ðó
    Èçâèíèòå, óâàæàåìûé AlexT!

    Íî, ÿ íå áóäó áîëüøå ó÷àñòâîâàòü â äàííîé äèñêóññèè. Åñëè ïî ýòèì èëè äðóãèì âîïðîñàì, Âàì áóäåò èíòåðåñíî ìîå ìíåíèå, ãîòîâ îáñóäèòü èõ â äðóãîì ðàçäåëå ôîðóìà.

  8. òó÷êà
    #23
    ×èòàòåëü Íåäóã.Ðó
    Óâ. äîêòîð Æèâîâ!



    Ïðèâîæó çàìåòêó èç âûøåóïîìÿíóòîãî àâñòðàëèéñêîãî ðóêîâîäñòâà ïî ÂÏ×:



    Immunosuppressed Patients

    Persons who are immunosuppressed because of HIV or other reasons may not respond as

    well as immunocompetent persons to therapy for genital warts, and they may have more

    frequent recurrences after treatment. Immunosuppressed women should have cervical Pap

    smears annually, with early referral for colposcopy if abnormalities are detected. Squamous

    cell carcinomas arising in SILs resembling genital warts occur more frequently among

    immunosuppressed persons.



    Äëÿ âûÿâëåíèÿ òàêîé èììóíîñóïðåñèè òðàäèöèîííàÿ èììóíîãðàììà è ïðèìåíÿåòñÿ âî âñåì ìèðå.

    Òàêèì îáðàçîì, êàê ìåòîä âòîðîãî ýòàïà èììóíîëîãè÷åñêîãî îáñëåäîâàíèÿ (ïîñëå àíàìíåçà), èììóíîãðàììà ìîæåò áûòü ïîëåçíà â ïðîãíîçå òå÷åíèÿ , îòâåòà íà ëå÷åíèå ÂÏ×-èíôåêöèè è åå ðåöèäèâîâ.



    Êàê ïðàâèëî, êàòåãîðè÷åñêèå âûñêàçûâàíèÿ (î ïîëíîé áåñïîëåçíîñòè èììóíîãðàììû ïðè ÂÏ×, íàïðèìåð) â ìåäèöèíå ðåäêî îêàçûâàþòñÿ ïðàâèëüíûìè.

  9. Ëåíà 2000
    #24
    ×èòàòåëü Íåäóã.Ðó
    Ñêàæèòå íà ìèëîñòü Àëåêñ,

    Ãäå Âû íàøëè â äàííîì ãàéäëàéíå è ãäå ëèáî åùå, õàðàêòåðèñòèêè èììóíîãðàììû, êîòîðûå áû ãîâîðèëè î òîì êîíêðåòíî, ÷òî äàííàÿ ïàöèåíòêà èìååò ïîâûøåííûé ðèñê ðåöèäèâà êîíäèëëîì, öåðâèêàëüíîãî ðàêà è ò.ï. êîíêðåòíûå âåùè. Ãäå ïðÿìîå óêàçàíèå, ÷òî èììóíîãðàììó áîëüíûì HPV ñâÿçàííûì áîëåçíÿì íàäî îáÿçàòåëüíî äåëàòü äëÿ ÷åãî-ëèáî? Ãäå åñòü óêàçàíèÿ, ÷òî èììóíîãðàììà èìåþò íåêóþ äîïîëíèòåëüíóþ öåííîñòü ê îáû÷íîìó ñáîðó àíàìíåçà? Ãäå öåííîñòü ýòîãî èññëåäîâàíèÿ îõàðàêòåðèçîâàíà ñïåöèôè÷íîñòüþ è ÷óâñòâèòåëüíîñòüþ?



    Áåçóñëîâíî, èììóíîêîìïðîìåòèðîâàííûé áîëüíîé, åñòü èììóíîêîìïðîìåòèðîâàííûé áîëüíîé. Íî ÷òî êîíêðåòíîãî íàì ñêàæóò ïîêàçàòåëè èììóíîãðàììû? ×òî ïîáóäèòåëüíîãî ê íåêèì êîíêðåòíûì äåéñòâèÿì è îöåíêàì äîáàâÿò ê àíàìíåçó è ò.ä. Òîëüêî êîíêðåòíîãî ïîæàëóéñòà!



    P.S. Âàì äëÿ èíôîðìàöèè, Àëåêñ. Îçîí è âñåñèëüíûé îðãàíèçì, êîòîðûé ñàì ñåáÿ áåç "íåíóæíûõ" è "òóïèêîâûõ" â ñâîåì ðàçâèòèè ëåêàðñòâ è îïåðàöèé ÿêîáû èçëå÷èâàåò ÷óòü ëè íå îò âñåõ áîëåçíåé ïîä äåéñòâèåì îçîíà ó Âëàäèìðà ßêîâëåâè÷à ïðè âñåì, îò ðàêà äî, ïðîñòèòå, òðèïåðà.

  10. Veronica
    #25
    ×èòàòåëü Íåäóã.Ðó
    Îïÿòü ñêàæó: äà ïðè ÷åì çäåñü îçîíîòåðàïèÿ???



    Èíòåðåñíàÿ ëîãèêà ïîëó÷àåòñÿ :

    Ñëîâî ïðîòèâ Æèâîâà - ýòî ñëîâî ïðîòèâ EBM, ñëîâî çà Çàéöåâà - ðåêëàìà îçîíîòåðàïèè?

  11. ËèÌà
    #26
    ×èòàòåëü Íåäóã.Ðó
    Óâàæàåìûé Àëåêñ,



     íàñòîÿùåå âðåìÿ íà Çàïàäå, â ÑØÀ â ÷àñíîñòè, íèêîãî ëå÷åíèÿ ïîëîâîãî ïàðòí¸ðà ïàöèåíòà ñ âûÿâëåíîé ïàïèëëîìàâèðóñíîé èíôåêöèåé íå ïðîâîäèòñÿ, åñëè ó ïåðâîãî, êîíå÷íî, íåò êàêèõ ëèáî êîñìåòè÷åñêèõ æàëîá, êàê òî - áîðîäàâêè. Ìàëî òîãî, â ðàìêàõ êëèíè÷åñêîé ìåäèöèíû íå ïðîâîäÿò äàæå òåñòèðîâàíèÿ ïîëîâîãî ïàðòíåðà, ò.ê. ðåçóëüòàò òåñòà íå âíåñ¸ò êîððåêòèðîâêè â òàêòèêó ëå÷åíèÿ. À ëå÷àò/íàáëþäàþò òîëüêî æåíùèíó. Äàííàÿ òàêòèêà ïîäðîáíî îïèñàíà â àïðåëüñêîì íîìåðå JAMA çà 2002 ãîä (" 2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalites" JAMA, 2002 vol. 287 No 16, 2120-29). Ýòî ñàìîå ëó÷øåå è ýôôåêòèâíîå íà ñåãîäíÿøíèé äåíü, ïîýòîìó ðåêîìåíäóþ âñåì ðîññèéñêèì ñïåöèàëèñòàì âîîðóæèòñÿ èìåííî ýòèì ðóêîâîäñòâîì. Ïîñëåäíåå ðóêîâîäñòâî ïî ðàííåé äèàãíîñòèêå öåðâèêàëüíîé íåîïëàçèè è ðàêà èçëîæåíî â íîÿáðüñêîì íîìåðå Cancer Journal for Clinicians çà 2002 ãîä ("American Cancer Society guideline for the early detection of cervical neoplasia and cancer" CA Cancer J Clin. 2002 Nov-Dec;52(6):342-62. Review) Ïî ïîâîäó òåñò-ñèñòåì. Äëÿ âðà÷à-êëèíèöèñòà âàæíî çíàòü íå êîíêðåòíûé òèï HPV, à ãðóïïó, ê êîòîðîé îí îòíîñèòñÿ: high-risk group (HPV-16/-18/-31/-33/-35/-39/-45/-51/-52/-56/-58/-59/-66/-68/-69)or low-risk group (êóäà âõîäÿò 6,11 - îñíîâíûå òèïû âèðóñà, âûçûâàþùèå îñòðîêîíå÷íûå êoíäèëîìû). Ïîýòîìó, â ïåðâóþ î÷åðåäü øèðîêîå ïðèìåíåíèå â ïðàêòèêå ïîëó÷èë ñêðèíèíãîâûé Hybrid Capture® 2 High-Risk HPV DNA Test, ïðîèçâîäèìûé êîìïàíèåé Dygene. Äàííûé òåñò, ïîëó÷èâøèé îäîáðåíèå FDA, îñíîâàí íà âûÿâëåíèè ñïåöèôè÷íûõ ÐÍÊ-ÄÍÊ êîìïëåêñîâ ïóò¸ì èììóíîôåðìåíòíîãî àíàëèçà (ïîäðîáíóþ èíôîðìàöèþ ìîæíî ïî÷åðïíóòü íà ñàéòå êîìïàíèè: Digene.com).

    Êàêèå æå ðåêîìåíäàöèè äàòü áîëüíîé ïî ïîâîäó ïàðòí¸ðà?  ïåðâóþ î÷åðåäü, íåîáõîäèìî îáúÿñíèòü, ÷òî íàëè÷èå ÏÎÑÒÎßÍÍÎÃÎ ïîëîâîãî ïàðí¸ðà àâòîìàòè÷åñêè ïåðåâîäèò æåíùèíó â ãðóïïó íèçêîãî ðèñêà äëÿ ðàçâèòèÿ ðàêà øåéêè ìàòêè. Äåéñòâèòåëüíî, êàê áûëî ïîêàçàíî âñåìè ñåðü¸çíûìè ýïèäåìèîëîãè÷åñêèìè èññëåäîâàíèÿìè îñíîâíîé ðèñê äëÿ öåðâèêàëüíîé ïàòîëîãèè - ÷àñòàÿ ñìåíà ïàðòí¸ðà. Ãèïîòåòè÷åñêè, ïîëîâàÿ íåðàçáîð÷èâîñòü ïðèâîäèò ê ïîñòîÿííîé ýêñïîçèöèè ê ñâåðõ ìàëûì äîçàì HPV âèðóñîâ ðàçëè÷íûõ òèïîâ, êîòîðûå íå ìîäóëèðóþò ñïåöèôè÷íûõ çàùèòíûõ ìåõàíèçìîâ, ÷òî ïðèâîäèò ê ïåðñèñòèðîâàíèþ âèðóñà. Äîçà âèðóñà (viral load) àññîöèèðîâàía ñ àìïëèòóäîé ãóìîðàëüíîãî îòâåòà, â ÷àñíîñòè ñ òèòðîì IgG è ïîÿâëåíèåì ñûâîðîòî÷íîãî IgA, êîòîðûé â ñâîþ î÷åðåäü àññîöèèðîâàí ñ èñ÷åçíîâåíèåì ÄÍÊà âèðóñà èç êëåòîê (viral clearance).



    Ïðîôèëàêòè÷åñêàÿ âàêöèíà, íà îñíîâå HPV16 âèðóñî-ïîäîáíûõ ÷àñòèö è ëå÷åáíàÿ âàêöèíà íà îñíîâå ðåêîìáèíàíòíîãî Å7 èëè Å7 ñèíòåòè÷åñêèõ ïåïòèäîâ, åù¸ íå ñòîÿò íà âîîðóæåíèè êëèíè÷åñêîé ìåäèöèíû. Íî òåìà áåçóñëîâíî èíòåðåñíàÿ, òðåáóþùàÿ îòäåëüíîé äèñêóññèè.



    Ïî ïîâîäó ðîëè èììóíîãðàì â êëèíè÷åñêîé ìåäèöèíå - öåëèêîì ðàçäåëÿþ ìíåíèå äîêòîðà Æèâîâà.



    Ñ óâàæåíèåì,



    Åâãåíèé Ñòóäåíöîâ, M.D.

    Papillomavirus Laboratory

    Albert Einstein College of Medicine

  12. Ìóõà öå-öå
    #27
    ×èòàòåëü Íåäóã.Ðó
    Ñïàñèáî, ä-ð Ñòóäåíöîâ, çà ó÷àñòèå â äèñêóññèè. Åñëè Âû ðàáîòàåòå â Montefiore Hospital â Áðîíêñå (îäíà èç êëèíè÷åñêèõ áàç Albert Einstein College of Medicine), òî ÿ èìåë ÷åñòü òàì íåìíîãî ó÷èòüñÿ â 1997 ã. â óðîëîãè÷åñêîì äåïàðòàìåíòå, êîòîðûé âîçãëàâëÿåò ïðîô. A. Melman. Íàäåþñü, ÷òî Âû è äàëüøå áóäåòå íàõîäèòü âðåìÿ íà ó÷àñòèå â ôîðóìå è âíîñèòü ñâîé ïîñèëüíûé âêëàä â ðàñïðîñòðàíåíèå ñåãîäíÿøíèõ ìåäèöèíñêèõ çíàíèé. Ýòî òàê íåîáõîäèìî íàøèì êîëëåãàì è âñåì íàì.

  13. vbkfz777
    #28
    ×èòàòåëü Íåäóã.Ðó
    Âîò åù¸ îäèí âåñüìà ïîëåçíûé äîêóìåíò



    Sexually Transmitted Diseases Treatment Guidelines - 2002

    Centers for Disease Control and Prevention.

    MMWR Recomm Rep. 2002 May 10;51(RR-6):1-78.



    Ïîëíûé òåêñò ìîæíî íàéòè çäåñü:



    http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5106a1.htm



    Ñ óâàæåíèåì,



    Å.Å. Ñòóäåíöîâ

  14. Sanna
    #29
    ×èòàòåëü Íåäóã.Ðó
    Óâàæàåìûé äîêòîð Ñòóäåíöîâ!



    Ðàä âîçìîæíîñòè çàäàòü âîïðîñû ñïåöèàëèñòó, çàíèìàþùåìóñÿ ïàïèëëîìàâèðóñàìè.



    Åñëè âû îáðàòèëè âíèìàíèå íà íàøó äèñêóññèþ, íàâåðíîå Âû çàìåòèëè, ÷òî èìåííî ýòî ðóêîâîäñòâî ÑDC ìû è îáñóæäàëè,

    è ìîè çàìå÷àíèÿ êàñàëèñü îáîñíîâàííîñòè ïðèâåäåííûõ òàì ðåêîìåíäàöèé ïî ÷àñòè ëå÷åíèÿ ïàðòíåðà ïðè ïàïèëëîìàâèðóñàì .

    Êñòàòè, ñìîòðåë åæåãîäíûé ñáîðíèê ïî äîêàçàòåëüíîé ìåäèöèíå Clinical evidence, èçäàâàåìûé BMJ, ïåðåâîä êîòîðîãî òåïåðü ïðîäàåòñÿ â "Ìåäêíèãå".  ÷àñòè 6 çà 2003 ãîä áûëà ñòàòüÿ ïî ïàïèëëîìàâèðóñàì.

    Êëèíè÷åñêèé âîïðîñ - ýôôåêòèâíîñòü ëå÷åíèÿ ïàðòíåðà ïðè ÎÊ è ïðèìåíåíèÿ ïðåçåðâàòèâîâ.

    Îáçîð ëèòåðàòóðû îò 2001 ãîäà, àíãëèéñêîå èçäàíèå àâãóñò 2002 : êîíòðîëèðóåìûõ êëèíè÷åñêèõ èñïûòàíèé ïî ýòîé òåìå íå íàéäåíî.

    Âûâîä: ýôôåêòèâíîñòü íå äîêàçàíà.



    Âîçíèêàåò âîïðîñ: ïî÷åìó ñïåöèàëèñòû ïî äîêàçàòåëüíîé ìåäèöèíå íå çàìåòèëè ñòàòåé, êîòîðûå ëåãëè â îñíîâó ðåêîìåíäàöèé CDC? Ìîæåò, ýòè ñòàòüè íå îòâå÷àþò òðåáîâàíèÿì äîêàçàòåëüíîé ìåäèöèíû?.

    Êñòàòè, â ñáîðíèêå âûâîäû 3-õ òèïîâ:

    - Ýôôåêòèâíîñòü äîêàçàíà

    - Ýôôåêòèâíîñòü íå äîêàçàíà

    - Ýôôåêòèâíîñòü ìàëîâåðîÿòíà.

    Êàê âèäèì, ìíåíèå î ëå÷åíèè ïàðòíåðà - ýòî 2-òèï, à íå òðåòèé.

    __________________________________________________ _

    äëÿ äîêòîðà Æèâîâà :

    Ïðîøó íå ñ÷èòàòü ýòè çàìåòêè íàïàäêàìè íà EBM. Ïðîñòî äàëåêî íå âñå ðåêîìåíäàöèè äàæå â çàðóáåæíûõ èñòî÷íèêàõ îñíîâûâàþòñÿ íà äàííûõ, îòâå÷àþùèõ æåñòêèì òðåáîâàíèÿì EBM. Âåäü è íà çàïàäå EBM îõâàòûâàåò íàìíîãî ìåíüøå ìåäèöèíñêèõ çíàíèé (ïîêà), ÷åì ïðèìåíÿåò ñîâðåìåííûé âðà÷ â ñâîåé ïðàêòèêå.

    Ó íàñ æå ÷àñòî àíãëîÿçû÷íûé = îñíîâàíûé íà äàííûõ äîêàçàòåëüíîé ìåäèöèíû.

    ×òî êàñàåòñÿ ðóêîâîäñòâ, òî èõ íóæíî ÷èòàòü , à íå ïðåêëîíÿòüñÿ (âïðî÷åì , ýòî áîëüøå â ñòîðîíó Vladlena) .

    __________________________________________________ __





    Ïîçâîëüòå çàäàòü íåñêîëüêî ïðàêòè÷åñêèõ âîïðîñîâ:

    - êàê ÷àñòî â âàøåé ïðàêòèêå êëèíè÷åñêèå ïðîÿâëåíèÿ ÂÏ× (ïëîñêèå êîíäèëîìû, íàïðèìåð) åñòü, à òåñò íà ÂÏ× îòðèöàòåëüíûé? ×òî äåëàåòñÿ â òàêèõ ñëó÷àÿõ?

    - êàêîå ìåñòî ó âàñ çàíèìàåò ÏÖÐ íà ïàïèëëîìàâèðóñû? Òîëüêî íàó÷íûå èññëåäîâàíèÿ èëè â ïðàêòèêå òîæå ïðèìåíÿþò?

    - êàêàÿ ñåé÷àñ íàèáîëåå ÷àñòî ïðèìåíÿþùàñÿ êëàñññèôèêàöèÿ òèïîâ ÂÏ×? Ïðèìåíÿåòñÿ ëè òåðìèí ãðóïïà ñðåäíåãî ðèñêà?

    - êàêàÿ ÷àñòîòà âñòðå÷àåìîñòè ÂÏ× 66,68,69 òèïîâ (ò.å òåõ, êîòîðûå â íàøåé ëàáîðàòîðèè ìû íå ìîæåì âûÿâèòü)?

    - âñòðå÷àëè ëè Âû ðàáîòû ïî ýôôåêòèâíîñòè èëè íåýôôåêòèâíîñòè ïðèìåíåíèÿ ïðè ÂÏ× ïðåïàðàòîâ ãðóïïû àöèêëîâèðà , è â ÷àñòíîñòè âàëòðåêñà?

  15. groz
    #30
    ×èòàòåëü Íåäóã.Ðó
    Óâàæàåìûé Àëåêñ,



    Óâèäåâ Âàø êîììåíòàðèé ïî ïîâîäó CDC ðåêîìåíäàöèé, ïðèãëÿäåëñÿ è îáíàðóæèë âòîðóþ è òðåòüþ ñòðàíèöó îáñóæäåíèé ïî íàøåé òåìå. Èçâèíèòå, åñëè áû çíàë, íèêîãäà áû íå ïîðåêîìåíäîâàë èñòî÷íèê, êîòîðûé âûçâàë öåëóþ áàòàëèþ è âçðûâ ýìîöèé. Ñîãëàñåí, ÷òî åñëè èíñòðóêöèÿ èëè ðåêîìåíäàöèÿ ïîëíîñòüþ íå ðåøàåò ïðîáëåìó, îíà íå ìîæåò áûòü íàçâàíà ñîâåðøåííîé. Íî... Íî CDC ðåêîìåíäàöèè íàïèñàíû íå áåçóìíûì ÷èíîâíèêîì èç àìåðèêàíñêîãî ìèíèñòåðñòâà çäðàâîîõðàíåíèÿ èëè ìàëü÷èêîì-ìàæîðîì, ðåøèâøèì, çà îïðåäåë¸ííóþ ìçäó, óâåêîâå÷èòü èíôðàêðàcíóþ ïóøêó, ñïîñîáíóþ çàïåëåíãîâàòü è óíè÷òîæèòü ëþáîãî ãàäà â ñàìîé îòäàë¸ííîé òî÷êå ìîåãî îðãàíèçìà; ðåêîìåíäàöèè CDC - ýòî êîíñåíñóñ ê êîòîðîìó ïðèøëè âåäóùèå ñïåöèàëèñòû âñåãî ìèðà â îáëàñòè äîêàçàòåëüíîé ìåäèöèíû. Äîêàçàòåëüíàÿ ìåäèöèíà - ýòî òàêàÿ øòóêà ó êîòîðîé, ãîâîðÿ ÿçûêîì êëàññèêè, âñåãäà ñóùåñòâóåò "Ñåäüìîå" äîêàçàòåëüñòâî, êîòîðîå, ïðè æåëàíèè, ìîæåò áûòü ïðåäúÿâëåíî.

    Èòàê, îáî âñ¸ì ïî ïîðÿäêó. Ðàáîòà Ä-ðà Krebs et al. îïóáëèêîâàííàÿ â æóðíàëå Am. J. Obstet. Gynecol. â 1991 è ïðèâîäèìàÿ â ññûëêàõ CDC, íå ÿâëÿòñÿ åäèíñòâåííîé è îñíîâîïîëàãàþùåé; îíà áûëà ëèøü ëîãè÷åñêèì ïðîäîëæåíèåì öåëîãî ðÿäà êëèíè÷åñêèõ íàáëþäåíèé, ñäåëàííûõ ðàçëè÷íûìè ãðóïïàìè ó÷¸íûõ è âðà÷åé. Îá ýòîì ìîæíî óçíàòü èç çàìå÷àòåëüíîãî îáçîðà " Management of the patient with an abnormal Papanicolaou test" êàíàäñêîãî Ä-ðà Alex Ferenczy îïóáëèêîâàííîãî â 1993 ãîäó â æóðíàëå Obstetrics and Gynecology Clinics of North America (Vol. 20, No. 1 p. 189-202).

    Âîò öèòàòà:



    "...growing number of observation has suggested that monogamous sexual partnership is not associated with reinfection of the partners. For example, in a long-term follow-up study of 2963 women successfully treated with cryotherapy for SIL/CIN of all grades, recurrence rates of new lesions were not higher than that reported in the general and sexually active population, i.e. 4/1000. (ref.1)...In the author's ongoing but yet unpublished study, recurrence rates of vulvar warts after single CO2 laser therapy have been the same (50%) whether the male sexual partner (with HPV-positive lesions) were treated and used condoms or were not treated and did not use condoms. [ref. 2] Similar observations were reported in a recent study of more than 380 patients treated for genital warts and CIN [ref.3]."



    ref.1 - Richard, R.M. "Causes and managment of carvical intraepithelial neoplasia." Cancer, 60: 1951-55, 5, 1980

    ref.2 - Äàííàÿ ðàáîòà áûëà îïóáëèêîâàíà â æóðíàëå J. Gynecol. Surg. çà 1995;Vol.11 No.1 p. 41-50 "Treating vaginal and external anogenital condylomas with electrosurgery vs CO2 laser ablation."

    ref.3 - Larsson, G. et al. " A comparison of complications of laser and cold knife conization." Obstet. Gynecol. Vol.62 p.213, 1983



     òîæå âðåìÿ áûëà ðàáîòà ó÷¸íûõ èç Þæíîé Àìåðèêè:

    "The mail factor in the incident of condiloma of the cervix and intraepithelial cervical neoplasms." Ginecol. Obstetr. Mex. 1991 Nov; Vol.59, p. 335-40

    Conclusion: There were persistence and recidiva, nonsignificant, when the man had received treatment suggesting that the treatment does not alter the appearence of condyloma, nor cervical intraepithelial neoplasia.



    ×òî æå áûëî ïîòîì? Îêåé, äîêàçàëè, áîëüøå íè÷åãî íå íàäî. Ñîâñåì íåò.

    Áûëè ðàáîòû, áûë ÒÐÓÄ, áûëè äîêàçàòåëüñòâà:

    Âîò áðàçèëüñêàÿ ðàáîòà:

    Teixeira, J.C. et al. " Effects of the male sexual partner evaluation in the relapses risk in women treated for a HPV-induced genital lesions." International Papillomavirus Conference, September 1-7, Costao do Santinho, Florianopolis, Brasil 2001.

    Conclusion: The evaluation of men in this study did not benefit woman regarding the risk of the recurrence of HPV genital lesions. The HPV genital lesions in men were not correlated with relapses, of diseases in women. These observations do not support the hypothesis that non evaluated men would be an important cause of relapses of HPV lesions in women.

    Âîò íàì ôðàíöóçñêàÿ:

    Aynaud, O. et al. "Cytologyc detection of human papillomavirus DNA in normal male urethral samples." Urology. 2003 Jun;61(6):1098-101.

    Conclusion: Our results show that HPV-DNA positivity in the absence of clinically or colposcopically detected lesions is a rare event. Although sensitive enough, cytology is not specific, and its use as a screening tool may lead to a high number of false-positive results.



    Åñëè íå óáåäèë, ãîòîâ íàéòè äîïîëíèòåëüíûå äîêàçàòåëüñòâà, êîòîðûå ÿ âñòðå÷àë îòäåëüíûìè îáçàöàìè â ðàçëè÷íûõ ðàáîòàõ, ò.ê. ïóáëèêàöèè íà äàííóþ òåìó ñïåöèàëüíûì èçäàíèåì, áåç êàêèõ-ëèáî äîïîëíåíèé è óòî÷íåíèé, ìíîãèå èññëåäîâàòåëè ñ÷èòàþò ïðîñòî íåñêðîìíûì.



    Ìîæíî ëè äîïóñòèòü, ÷òî âñå ýòè ðàáîòû îøèáî÷íû? Ìîæíî. Íî îïðîâåðãíóòü èõ ñìîæåò òîëüêî äîêàçàòåëüíàÿ ìåäèöèíà, êîòîðîé, â îòëè÷èå îò âñÿêîé "áðàõìàïóòðû", ïðèñóùå óíèêàëüíîå ñâîéñòâî ñàìîêîððåêöèè.



    Íà äàííîì ýòàïå "ðàçâèòèÿ" ðîññèéñêîé ìåäèöèíû íàì íåîáõîäèìî ñëóøàòü è âïèòûâàòü ìèðîâîé îïûò, î ÷¸ì íåîäíîêðàòíî ãîâîðèëîñü íà ýòîì ôîðóìå. À èíà÷å... Èíà÷å: "Òîëüêî íàì è ñëàâû, ÷òî êîâàíûå áëîõè".



    Ïðîñòèòå, óâë¸êñÿ. Îòâåòû íà Âàøè âîïðîñû äàì çàâòðà. Íüþ-Éîðêñêîå âðåìÿ - 3 am.



    Ñ ãëóáîêèì óâàæåíèåì,



    Å.Å. Ñòóäåíöîâ

Êëèíèêà ñòîìàòîëîãèè è êîñìåòîëîãèè â Ìîñêâå

Ìåòêè ýòîé òåìû

Âàøè ïðàâà

  • Âû ìîæåòå ñîçäàâàòü íîâûå òåìû
  • Âû ìîæåòå îòâå÷àòü â òåìàõ
  • Âû íå ìîæåòå ïðèêðåïëÿòü âëîæåíèÿ
  • Âû íå ìîæåòå ðåäàêòèðîâàòü ñâîè ñîîáùåíèÿ
  •